Programmed cell death protein-1 inhibitors for immunotherapy of advanced nonmelanoma skin cancer: showing early promise

2016 ◽  
Vol 175 (6) ◽  
pp. 1150-1151 ◽  
Author(s):  
E. Soura ◽  
V. Chasapi ◽  
A.J. Stratigos
Keyword(s):  
Cell Death ◽  
Skin Cancer ◽  
Programmed Cell Death ◽  
Nonmelanoma Skin Cancer ◽  
Cell Death Protein

Expression of programmed cell death protein 4 in nonmelanoma skin cancer compared with psoriasis and normal skin, a preliminary study

2016 ◽  
Vol 13 (2) ◽  
pp. 77-82
Author(s):  
Mona R.E. Abdel-Halim ◽  
Faisal N. Mohammed ◽  
Khadiga S. Sayed ◽  
Dalia M. Abouelfadl ◽  
Amina A. Gamal El-Din ◽  
...  
Keyword(s):  
Cell Death ◽  
Skin Cancer ◽  
Programmed Cell Death ◽  
Normal Skin ◽  
Nonmelanoma Skin Cancer ◽  
Preliminary Study ◽  
Cell Death Protein

Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer

2016 ◽  
Vol 176 (2) ◽  
pp. 498-502 ◽  
Author(s):  
J.K. Winkler ◽  
R. Schneiderbauer ◽  
C. Bender ◽  
O. Sedlaczek ◽  
S. Fröhling ◽  
...  
Keyword(s):  
Cell Death ◽  
Skin Cancer ◽  
Programmed Cell Death ◽  
Nonmelanoma Skin Cancer ◽  
Programmed Cell Death 1

scholarly journals Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Ece Esin
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Checkpoint Inhibitors ◽  
Innate Immune ◽  
Small Subset ◽  
New Class ◽  
Combination Strategies ◽  
Combination Methods ◽  
Immune Editing ◽  
Cell Death Protein

In the last decade, we have gained a deeper understanding of innate immune system. The mechanism of the continuous guarding of progressive mutations happening in a single cell was discovered and the production and the recognition of tumor associated antigens by the T-cells and elimination of numerous tumors by immune-editing were further understood. The new discoveries on immune mechanisms and its relation with carcinogenesis have led to development of a new class of drugs called immunotherapeutics. T lymphocyte-associated antigen 4, programmed cell death protein 1, and programmed cell death protein ligand 1 are the classes drugs based on immunologic manipulation and are collectively known as the “checkpoint inhibitors.” Checkpoint inhibitors have shown remarkable antitumor efficacy in a broad spectrum of malignancies; however, the strongest and most durable immune responses do not last long and the more durable responses only occur in a small subset of patients. One of the solutions which have been put forth to overcome these challenges is combination strategies. Among the dual use of methods, a backbone with either PD-1 or PD-L1 antagonist drugs alongside with certain cytotoxic chemotherapies, radiation, targeted drugs, and novel checkpoint stimulators is the most promising approach and will be on stage in forthcoming years.

Discovery of modulator for PD-1/PD-L1 interaction by molecular simulation and bioassay

2021 ◽  
Author(s):  
guangping Li ◽  
Haiqiong Guo ◽  
linan zhao ◽  
Huixian Feng ◽  
Huawei He ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Molecular Simulation ◽  
Immune Escape ◽  
Cell Death Protein

The combination of the human programmed cell death protein 1 (hPD-1) and its ligand hPD-L1 activates the immune escape of tumors, and the blockage in PD-1/PD-L1 involved pathway can enhance...

Sign in / Sign up

Export Citation Format

Share Document